BTK and chronic neutrophilic leukemia: In addition to AML and MDS, aberrant activation of BTK has been detected in patients of chronic neutrophilic leukemia (CNL) with G-CSFR mutations and these cells show high sensitivity to ibrutinib treatment (45).